RE:RE:For Notable on Roche Bispecific Antibodies in development askretka - thank you for recognizing the proper spelling of my screen name. As I explained to westcoast in an earlier post, only my detractors use the misspelling.
To place the Chaugi-Roche relationship into context, Chaugi Pharmaceuticals became part of the Roche Group in 2002, with Roche retaining approximately 60% controlling interest in the company.
Next, with respect to the list of oncology bispecifc antibodies in posted link, you will see that Roche has out-licensed most of these bispecifics to Chugai primarily because it would appear to me that Roche can not see what to do with them as most of the antiibody inhibitors have failed in other trials or have experienced reistance over time, such as the TIGIT, SERD degraders, MEK and RET inhibitors.
What is of interest however, was Roche's in-licensing of the anti-latent TGF-Beta1 monoclonal antibody which has an effect on the tumor microenvironment (TME). Speculatively it would appear that Roche is interested in this bispecific for its potential application in renal failure (glomerulonephritis) and kidney cancer in combination with Tecentriq. It woulld appear that Roche's interest in changing the resistance of the TME to a more favorable environment for the addition of other I/O agents like Tecentriq, follows the objective that ONCY has already clinically demonstrated with pelareorep.
ONCY has effectively demonstrated that pelareorep can both "prime" and "train" the immune system, by first converting the TME into a less hostile environment for the addition of a follow-up immune checkpoint inhibitors and/or CAR-T therapies, and then creating a diversity of T-cells, including memory cells, to both kill cancer cells and surveil for others that may appear later.
The rest of the bispecifics antibodies that Chaugi listed as being in-licensed from Roche are similarly inconsequential to those list above, from what I can tell.